Go-to-market · life sciences · GTM strategy · UK
Life sciences go-to-market strategy
A life sciences go-to-market strategy decides who you sell to first, what you say to them and how the first conversations start.
GTM Quest plans it for biotech, pharmaceutical, CRO, CDMO and research suppliers, and we start the motion on day one rather than after a long report.
It is part of our life sciences marketing agency work.
Reviewed by GTM Quest · 27 October 2026 · 7 sources linked below
How a go-to-market plan runsdecide, then move
- 01Pick the first segmentWEEK 1ICP · ACCOUNTS
- 02Position and proveWEEKS 1 TO 3MESSAGE · EVIDENCE
- 03Start the channelsWEEKS 1 TO 4OUTBOUND · CONTENT
- 04Review and widenMONTHS 2 TO 3KEEP · CUT · NEXT
When the motion startsDay 1
01/ the buyer
Who decides in life sciences? several roles, one purchase
A customer choice in life sciences involves more people than the one who asked for a conversation.
Module 01 / 05
Large buying groups
Forrester's 2026 State of Business Buying reports that the typical buying decision now includes 13 internal stakeholders and nine external influencers.
Module 02 / 05
Research and development
Scientific and clinical leaders judge whether a service or technology fits the programme.
Module 03 / 05
Operations and quality
Quality, manufacturing and supply chain leaders check capacity, compliance and track record.
Module 04 / 05
Commercial and business development
Partnership and licensing teams look for suppliers and collaborators that extend a pipeline.
Module 05 / 05
Procurement
Procurement compares approved suppliers and sets the paperwork a vendor must complete.
Forrester's research puts 13 internal stakeholders and nine external influencers in a typical decision.
We map the roles at each named account before the first message goes out, because life sciences has scientific buyers, long evaluations and strict promotional rules.
02/ who to reach
Which life sciences segment should you start with? segment by the problem you solve
Start where your offer removes an urgent, owned problem, then widen.
Our ideal customer profile method decides which segment comes first.
For the wider life sciences service, see our life sciences marketing agency page.
03/ timing
Life sciences buying signals reach accounts when something changes
A signal tells you an account is more likely to care now, so outreach can be specific.
Module 01 / 05
Sector plan
The government's Life Sciences Sector Plan sets out a vision and an action plan to drive growth, innovation, and better health outcomes, which shapes where investment goes.
Module 02 / 05
Funding rounds
A raise or a partnership gives a biotech budget and a reason to hire suppliers.
Module 03 / 05
Pipeline milestones
A new trial phase or a filing creates needs for manufacturing, data and regulatory support.
Module 04 / 05
Hiring
Adverts for clinical, quality or CMC roles show which functions are being built.
Module 05 / 05
Events
Conference speaking slots and posters show which topics a company is working on.
Our signal-based selling guide covers how signals are weighted and routed to sellers.
04/ how it runs
How a go-to-market plan runs motion first, system around it
Start with named accounts
We agree the first segment, build the account list and start real conversations while the rest is set up.
Map the buying group
For each priority account we map the roles that own the problem, review the risk and sign.
Switch on signals and channels
Signals, sequences, content and ads are built around the motion that is already running.
Score and hand over
Engagement is scored by account, and sales receives context, not just a name.
Review and widen
We keep what produces meetings, cut what does not, and move to the next segment.
Our lead scoring guide explains how engagement becomes a sales priority.
05/ rules
Life sciences marketing and the rules that apply what the sources say
Medicines promotion and regulation shape what a supplier can say and to whom.
Module 01 / 05
Medicines regulator
The MHRA regulates medicines, medical devices and blood components for transfusion in the UK, so buyers expect suppliers to understand its remit.
Module 02 / 05
Industry body
The ABPI represents UK research-based pharmaceutical companies and is the home of the ABPI Code of Practice.
Module 03 / 05
Code of practice
The Prescription Medicines Code of Practice Authority runs the UK process for the ABPI Code, so promotional material follows a code of its own.
Module 04 / 05
Corporate bodies
The ICO says you can email or text any corporate body, while sole traders and some partnerships are treated as individuals.
Module 05 / 05
Legitimate interests
B2B outreach to named people usually rests on legitimate interests, which the ICO sets out as a three-part test.
We work with your reviewers and do not give legal or regulatory advice.
06/ what you get
What a life sciences programme delivers six outputs you can inspect
01
Account list
The accounts worth reaching first, with the reason each one is on the list.
02
Role map
The roles that own the problem, review the risk and sign at each priority account.
03
Reviewed content
Messages and proof material written for each role and passed to your reviewers.
04
Signal feed
Changes that raise an account’s priority, routed to the right seller.
05
CRM and scoring
Every conversation traced to an account, a role and a channel.
06
Handover
Playbooks your team can run, and help hiring the people who will run them.
07/ the plan
What a life sciences go-to-market strategy decides five decisions
The plan is short, and each decision is one you can act on in the first week.
Module 01 / 05
Segment
Which type of account to pursue first, and which to leave for later.
Module 02 / 05
Buyer
Which roles own the problem, review the risk and sign.
Module 03 / 05
Message
What you say, in the words buyers use, with the proof behind it.
Module 04 / 05
Channels
Which routes reach the segment: outbound, search, events, partners.
Module 05 / 05
Handoff
How a conversation passes to sales with enough context to continue.
Our go-to-market strategy services page covers the general method.
08/ fit
Where should you start? pick your situation
What do you need most?
15 minutes · video or phone
Book 15 minutes on your life sciences pipeline
Tell us what you sell, who buys it and who reviews your content. We will tell you what we would run in the first week.
- 0115 minutes, video or phone
- 02A first-week plan
- 03A written next step after the call
Pick a day that suits · live availability
09/ questions
Life sciences go-to-market strategy FAQ
What B2B teams in life sciences ask before they start.
It finds the life sciences accounts likely to buy, the people inside them who decide, and starts reviewed conversations with them, starting on day one.
Biotech, pharmaceutical, CRO, CDMO and research suppliers.
The ICO says you can email or text any corporate body, while sole traders and some partnerships are treated as individuals; we keep a do not email list and work with your reviewers.
No. We run campaigns with your reviewers, who approve anything that needs approval.
No. We commit to starting the motion on day one and to reporting what produces meetings, not to outcomes nobody controls.
It depends on scope.
We scope and quote in writing after a 15-minute call.
Taking on new clients
Life sciences go-to-market strategy from day one
Fifteen minutes is enough to plan the first week.
11/ sources
Every source on this page
Each figure above links to one of these. All were opened and checked on 27 October 2026.
- the typical buying decision now includes 13 internal stakeholders and nine external influencersforrester.com
- sets out a vision and an action plan to drive growth, innovation, and better health outcomesgov.uk
- regulates medicines, medical devices and blood components for transfusion in the UKgov.uk
- represents UK research-based pharmaceutical companiesabpi.org.uk
- Prescription Medicines Code of Practice Authoritypmcpa.org.uk
- you can email or text any corporate bodyico.org.uk
- legitimate interests, which the ICO sets out as a three-part testico.org.uk